JP2022537359A5 - - Google Patents
Info
- Publication number
- JP2022537359A5 JP2022537359A5 JP2021575366A JP2021575366A JP2022537359A5 JP 2022537359 A5 JP2022537359 A5 JP 2022537359A5 JP 2021575366 A JP2021575366 A JP 2021575366A JP 2021575366 A JP2021575366 A JP 2021575366A JP 2022537359 A5 JP2022537359 A5 JP 2022537359A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable domain
- amino acid
- tcr
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135124A JP7875247B2 (ja) | 2019-06-18 | 2024-08-13 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
| JP2025135733A JP2025166209A (ja) | 2019-06-18 | 2025-08-18 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962862726P | 2019-06-18 | 2019-06-18 | |
| US62/862,726 | 2019-06-18 | ||
| US201962871793P | 2019-07-09 | 2019-07-09 | |
| US62/871,793 | 2019-07-09 | ||
| PCT/US2020/038142 WO2020257288A2 (en) | 2019-06-18 | 2020-06-17 | Mage-a4 t cell receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135124A Division JP7875247B2 (ja) | 2019-06-18 | 2024-08-13 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537359A JP2022537359A (ja) | 2022-08-25 |
| JP2022537359A5 true JP2022537359A5 (enExample) | 2023-06-23 |
| JP7730765B2 JP7730765B2 (ja) | 2025-08-28 |
Family
ID=74040867
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575366A Active JP7730765B2 (ja) | 2019-06-18 | 2020-06-17 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
| JP2024135124A Active JP7875247B2 (ja) | 2019-06-18 | 2024-08-13 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
| JP2025135733A Pending JP2025166209A (ja) | 2019-06-18 | 2025-08-18 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135124A Active JP7875247B2 (ja) | 2019-06-18 | 2024-08-13 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
| JP2025135733A Pending JP2025166209A (ja) | 2019-06-18 | 2025-08-18 | Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220324939A1 (enExample) |
| EP (1) | EP3986938A4 (enExample) |
| JP (3) | JP7730765B2 (enExample) |
| KR (1) | KR20220035387A (enExample) |
| CN (2) | CN118994364A (enExample) |
| AU (1) | AU2020295401A1 (enExample) |
| BR (1) | BR112021025548A2 (enExample) |
| CA (1) | CA3144253A1 (enExample) |
| CL (3) | CL2021003366A1 (enExample) |
| CO (1) | CO2022000281A2 (enExample) |
| IL (1) | IL289042A (enExample) |
| MA (1) | MA56548A (enExample) |
| MX (1) | MX2021015946A (enExample) |
| PH (1) | PH12021553152A1 (enExample) |
| WO (1) | WO2020257288A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| SG11201901634UA (en) * | 2016-09-23 | 2019-04-29 | Lion Tcr Pte Ltd | An hbv antigen specific binding molecules and fragments thereof |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MX2021015946A (es) * | 2019-06-18 | 2022-04-18 | Regeneron Pharma | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| EP4304726A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Mage-a4 peptide-mhc antigen binding proteins |
| CA3236237A1 (en) * | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| EP4536252A4 (en) * | 2022-06-08 | 2025-12-24 | Sheba Impact Ltd | Virus-specific recombinant T lymphocyte receptors and T lymphocytes containing them |
| US20260085105A1 (en) * | 2022-06-24 | 2026-03-26 | Amgen Inc. | Magea4 specific t cell receptors |
| EP4587046A1 (en) | 2022-09-14 | 2025-07-23 | CDR-Life AG | Mage-a4 peptide dual t cell engagers |
| IL320128A (en) | 2022-10-31 | 2025-06-01 | Regeneron Pharma | Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine |
| EP4393942A1 (en) * | 2022-12-29 | 2024-07-03 | Keshihua (Nanjing) Biotechnology Co., Ltd | Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr |
| AU2024214482A1 (en) | 2023-02-03 | 2025-08-07 | Zelluna Immunotherapy As | Anti-mage-a4 t cell receptors |
| CN119569851A (zh) * | 2023-09-05 | 2025-03-07 | 香雪生命科学技术（广东）有限公司 | 针对magea4的高亲和力tcr |
| WO2025233432A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| CN122344246A (zh) * | 2025-01-02 | 2026-07-07 | 中国科学院微生物研究所 | Mage-a4特异性t细胞受体筛选及抗肿瘤用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311914B2 (en) * | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| IL308831A (en) * | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| MX395611B (es) * | 2016-04-08 | 2025-03-25 | Adaptimmune Ltd | Receptores de celulas t. |
| KR20190065189A (ko) * | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T 세포 수용체 |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| MX2021015946A (es) * | 2019-06-18 | 2022-04-18 | Regeneron Pharma | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
-
2020
- 2020-06-17 MX MX2021015946A patent/MX2021015946A/es unknown
- 2020-06-17 CN CN202411136604.9A patent/CN118994364A/zh active Pending
- 2020-06-17 BR BR112021025548A patent/BR112021025548A2/pt unknown
- 2020-06-17 JP JP2021575366A patent/JP7730765B2/ja active Active
- 2020-06-17 KR KR1020227001750A patent/KR20220035387A/ko active Pending
- 2020-06-17 PH PH1/2021/553152A patent/PH12021553152A1/en unknown
- 2020-06-17 CA CA3144253A patent/CA3144253A1/en active Pending
- 2020-06-17 EP EP20827786.3A patent/EP3986938A4/en active Pending
- 2020-06-17 WO PCT/US2020/038142 patent/WO2020257288A2/en not_active Ceased
- 2020-06-17 CN CN202080053852.0A patent/CN114585646B/zh active Active
- 2020-06-17 AU AU2020295401A patent/AU2020295401A1/en active Pending
- 2020-06-17 MA MA056548A patent/MA56548A/fr unknown
- 2020-06-17 US US17/618,973 patent/US20220324939A1/en active Pending
-
2021
- 2021-12-15 IL IL289042A patent/IL289042A/en unknown
- 2021-12-15 CL CL2021003366A patent/CL2021003366A1/es unknown
-
2022
- 2022-01-17 CO CONC2022/0000281A patent/CO2022000281A2/es unknown
-
2024
- 2024-01-15 CL CL2024000119A patent/CL2024000119A1/es unknown
- 2024-08-13 JP JP2024135124A patent/JP7875247B2/ja active Active
-
2025
- 2025-08-18 JP JP2025135733A patent/JP2025166209A/ja active Pending
-
2026
- 2026-02-18 CL CL2026000490A patent/CL2026000490A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505679A5 (enExample) | ||
| JP2022518925A5 (enExample) | ||
| CN112739379B (zh) | 包含OX40抗原结合位点的Fc结合片段 | |
| JP2020501531A5 (enExample) | ||
| JP2023511417A5 (enExample) | ||
| ES2387809T3 (es) | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano | |
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| KR20170068458A (ko) | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 | |
| JP2016527286A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| JP2019535670A (ja) | Ｃｄ１３３結合剤およびその使用 | |
| JP2024521405A (ja) | Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質 | |
| JP2022548764A5 (enExample) | ||
| JP2022538475A5 (enExample) | ||
| JP2025004078A (ja) | ４－１ｂｂ結合タンパク質及びその用途 | |
| WO2022258678A1 (en) | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a | |
| CN115768467A (zh) | 用于治疗癌症和感染的针对NKp46的抗体及其构建体 | |
| JP2024533457A5 (enExample) | ||
| CN114616251B (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| JP2022513405A5 (enExample) | ||
| US12559538B2 (en) | PD-1 polypeptide variants | |
| WO2022149050A2 (en) | Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof |